Barclays maintains Overweight on Corteva, raises target to $91
Barclays analyst Benjamin Theurer has maintained an Overweight rating on Corteva (NYSE: CTVA) and raised the price target to $91 from $84, signaling a positive outlook for the agricultural inputs sector.
*this image is generated using AI for illustrative purposes only.
Barclays analyst Benjamin Theurer has maintained an Overweight rating on Corteva (NYSE: CTVA) while raising the price target to $91 from $84. The adjustment reflects a positive outlook on the agricultural inputs sector.
Rating and Price Action
The brokerage firm retained its Overweight stance on the stock, indicating a favorable risk-reward profile. The increase in the price target suggests a stronger valuation for the company's near-term performance.
| Metric | Previous | Revised |
|---|---|---|
| Rating | Overweight | Overweight |
| Price Target | $84 | $91 |
Corteva specializes in seed and crop protection solutions. The new price target provides a reference point for investors tracking the stock's potential trajectory.
What specific catalysts are driving the improved outlook for the agricultural inputs sector?
How might Corteva's product pipeline contribute to achieving the revised $91 price target?
What are the potential risks to Corteva's growth trajectory given current global economic conditions?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
